Clinical significance of Rho GDP dissociation inhibitor 2 in colorectal carcinoma

International Journal of Clinical Oncology

Volumn 17, Issue 2, 2012, Pages 137-142

  Fujita, Akihiko ^a   Shida, Atsuo ^a   Fujioka, Shuichi ^a   Kurihara, Hideaki ^a   Okamoto, Tomoyoshi ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal carcinoma; RhoGDI (Rho GDP dissociation inhibitor) 2

Indexed keywords

CHAPERONE; MESSENGER RNA; RHO GDP DISSOCIATION INHIBITOR 2; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; COLON RESECTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHO GDP DISSOCIATION INHIBITOR 2 GENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR BETA; RHO-SPECIFIC GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS;

EID: 84862891761     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0270-y     Document Type: Article

References (13)

1. August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303-324
2. McCormack PM, Burt ME, Bains MS et al (1992) Lung resection for colorectal metastases. 10-year results. Arch Surg 127:1403-1406
3. Goya T, Miyazawa N, Kondo H et al (1989) Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 64:1418-1421
4. Theodorescu D, Sapinoso LM, Conaway MR et al (2004) Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10:3800-3806
5. Olofsson B (1999) Rho guanine dissociation inhibitors: pivotal molecules in cellular signaling. Cell Signal 11:545-554
6. DerMardirossian C, Bokoch GM (2005) GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 15:356-363
7. Japanese Research Society for Colorectal Cancer (2006) Japanese classification of colorectal carcinoma. Kanehara, Tokyo
8. Tapper J, Kettunen E, El-Rifai W et al (2001) Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 128:1-6
9. Cui JW, Li WH, Wang J et al (2005) Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4:1718-1724
10. Yanagawa T, Watanabe H, Takeuchi T et al (2004) Overex-pression autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-b. Lab Invest 84:513-522
11. Hu LD, Zou HF, Zhan SX et al (2007) Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Res 17(6):1383-1389
12. Wu Y, Moissoglu K, Wang H et al (2009) Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci USA 106(14):5807-5812
13. Moissoglu K, McRoberts KS, Meier JA et al (2009) Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res 69(7):2838-2844